High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors

Clinical Infectious Diseases

Volumn 27, Issue 6, 1998, Pages 1510-1513

  Martínez, Esteban ^a   Gatell, José ^a   Morán, Yolanda ^a   Aznar, Esther ^a   Buira, Elisabet ^a   Guelar, Ana ^a   Mallolas, José ^a   Soriano, Eladio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; NUCLEOSIDE DERIVATIVE; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ENZYME BINDING; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINASE INHIBITION; SURVIVAL; VIRUS LOAD;

EID: 2442751100     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515019     Document Type: Article

References (17)

1. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336:1531-2.
2. Centers for Disease Control and Prevention. Update: trends in AIDS incidence. MMWR Morb Mortal Wkly Rep 1997; 46:165-73.
3. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443-5.
4. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymph-adenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-5.
5. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992; 166:1153-6.
6. Rogues AM, Dupon M, Ladner J, et al. Herpes zoster and human immunodeficiency virus infection: a cohort study of 101 coinfected patients. J Infect Dis 1993; 168:245.
7. Glesby MJ, Moore RD, Chaisson RE, the Zidovudine Epidemiology Study Group. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. J Infect Dis 1993; 168: 1264-8.
8. Alliegro MB, Dorruci M, Pezzotti P. et al. Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Clin Infect Dis 1996; 23:990-5.
9. Martínez E, Gatell JM, Vidal C, et al. Addition of a protease inhibitor (saquinavir, ritonavir, or indinavir) to baseline treatment in AIDS patients [abstract no 397]. In: Proceedings of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection (Hamburg, Germany). October 1997.
10. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41:1-19.
11. Croen KD. Latency and the consequences of reactivation of the varicella-zoster virus. In: Strauss SE, moderator. Varicella-zoster virus infections: biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:226-9.
12. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46:25.
13. Whitley RJ, Gnann JW Jr. Herpes zoster in patients with human immunodeficiency virus infection: an ever-expanding spectrum of disease. Clin Infect Dis 1995; 21:989-90.
14. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:370-5.
15. Cauda R, Grossi CE, Whitley RJ, Tilden AB. Analysis of immune function in herpes zoster patients: demonstration and characterization of suppressor cells. J Immunol 1987; 138:1229-33.
16. Margolick JB, Muñoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nature Med 1995; 7: 674-80.
17. + lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr 1996; 13:320-6.